Unlock regulatory insights with Watson. Learn More
Return to Docket

Declare That the Drug Products, Primidone Orally Disintegrating Tablets, 50 mg, 100 mg, 125 mg, and 250 mg, is Suitable for Consideration in an Abbreviated New Drug Application (ANDA)-CLOSED

Type: Non-Rule Making
KeyWord(s) primidone orally, disintegrating tablets, nda 09-170, mysoline, CDER, closed
Short title Declare That the Drug Products, Primidone Orally Disintegrating Tablets, 50 mg, 100 mg, 125 mg, and 250 mg, is Suitable for Consideration in an Abbreviated New Drug Application (ANDA)
Docket Item Code P
Center CDER

0 Comments

Click here to view all comments of this document.